Mark A. Smith
Technik-/Wissenschafts-/F&E-Leiter bei BRIGHT MINDS BIOSCIENCES INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Mark A. Smith
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BRIGHT MINDS BIOSCIENCES INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2022 | - |
Karriereverlauf von Mark A. Smith
Ehemalige bekannte Positionen von Mark A. Smith
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
VISTAGEN THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2016 | 01.12.2022 |
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Corporate Officer/Principal | 01.09.2012 | 01.10.2013 |
ASTRAZENECA PLC | Corporate Officer/Principal | 01.06.2000 | 01.09.2012 |
Ausbildung von Mark A. Smith
Yale University | Graduate Degree |
University of California San Diego | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Vereinigtes Königreich | 3 |
Operativ
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Graduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
VISTAGEN THERAPEUTICS, INC. | Health Technology |
ASTRAZENECA PLC | Health Technology |
BRIGHT MINDS BIOSCIENCES INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
Shire Plc /Old/
Shire Plc /Old/ Miscellaneous Commercial ServicesCommercial Services Shire is a global specialty pharmaceutical company marketing products to defined customer groups (specialist doctors). Sales and marketing is a core Shire competence. Shire combines investment in product development with careful attention to risk management. Shire currently focuses on three therapeutic areas - central nervous system disorders (CNS), gastrointestinal (GI) and renal diseases. Shire has particular expertise in ADHD as a result of its development and marketing of the leading brand in the US market, ADDERALL and the new once a day version, ADDERALL XR. The group has a sales and marketing infrastructure with a broad portfolio of products targeting the US, Canada, UK, Republic of Ireland, France, Germany, Italy and Spain. Shire covers other significant pharmaceutical markets indirectly through distributors. They have already appointed such distributors including, Australia, Denmark, Finland, Hong Kong, Israel, Malaysia, Norway, Philippines, Singapore, South Africa, South Korea and Thailand. It is founded in 1986 | Commercial Services |
- Börse
- Insiders
- Mark A. Smith
- Erfahrung